Boehringer Ingelheim shutters U.S. API plant

Boehringer Ingelheim says it's coping with excess capacity in its CMO network, and will shut down one of its three API-producing plants in the U.S. as a result.

The company will close up shop at its Petersburg, VA, facility, letting go of between 80 and 100 of its 340 workers by mid-year, FiercePharmaManufacturing reports. The plant had been in operation for 35 years, and that played a part in Boehringer's decision to shut it down, a spokeswoman said.

"The other reason is the production demands of the overall company," Jaime Belitz told FiercePharmaManufacturing. "Boehringer Ingelheim has four other chemical facilities in Europe. This is the only one in the U.S. With too much capacity, it doesn't make good business sense to keep it open."

The site produces APIs both for Boehringer's CMO customers and the company's internal use, part of a three-plant complex in Petersburg. The facilities produce nevirapine, telmisartan, dabigatran and the company's own Pradaxa.

- read the FiercePharmaManufacturing story

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

The CRO will transfer most of its Pennsylvania-based biologics laboratory functions to a new, 73,000-square-foot site on Devon Park in Wayne.

Monoclonal antibodies developer Xencor extended a strategic alliance formed in 2016 with Selexis with four commercial license agreements.